首页>投融资
BioCardia
增发
Biocardia, Inc.于1994年1月12日在特拉华州注册成立。该公司是一家临床阶段的再生医学公司,为具有大量未满足的医疗需求的心血管疾病开发新的治疗药物。他们的主要治疗候选药物是研究性CardiAMP细胞治疗系统,该系统提供自体骨髓衍生细胞疗法(使用患者自身细胞)治疗两种临床适应症:心脏病发作和慢性心肌缺血后发生的心力衰竭。
基本信息
-
公司全称BioCardia Inc
-
类型心血管疾病疗法开发商
-
产业领域药品研发/制造、生物药
-
公司人数15~50人
-
地址320 Soquel Way Sunnyvale California 94085;125 Shoreway Road Suite B SAN CARLOS CALIFORNIA 94070; US; Telephone: +16502260120;
-
联系电话1-650-2260120
-
邮箱info@biocardia.com
-
成立时间1999-01-01
投融资
-
2024-09-09增发720万美元未透露
-
2023-11-20增发130万美元未透露
-
2022-12-16上市后再融资360万美元未透露
-
2019-08-02上市未透露未透露
-
2016-04-15上市未透露未透露
- 加载更多
相关投融资企业
捐赠/众筹/授予
igaTx 是一家生物技术公司,开发工程化单体 IgA 中性粒细胞接合器,以释放中性粒细胞对癌症的肿瘤杀伤能力,以及针对传染病的工程化二聚体 IgA 杀伤能力。该公司在工程治疗性 IgA 方面的前沿方法基于 Jeanette Leusen 教授在乌得勒支医学中心(荷兰乌得勒支)进行的开创性工作,并广泛适用于许多不同疾病。
C轮
SiteOne Therapeutics, founded by Stanford University, is a biotechnology company focused on the development of long-acting analgesics, non-norcotic analgecis and diagnostic imaging agents for pain and cancer.In May 2023, SiteOne Therapeutics Inc received a grant for up to $15 million from the National Institute on Drug Abuse.In January 2017, the company raised $15 million in a series B round of financing
A轮
PsiOxus Therapeutics Ltd was formed from the merger of Myotec Therapeutics and Hybrid BioSystems in December 2010. The company is focused on the development of novel therapeutics that address cancer and other clinically unmet diseases.Myotec Therapeutics was a spin-out from Imperial Innovations and was set up to develop technology originated at Imperial College London. It focused on repurposing drugs for the treatment of cachexia, with the intention of out-licensing after completion of phase II studies.In June 2017, the company expanded its operations into a 21,000 sq ft state-of-the-art facility on the Abingdon Science Park in Oxfordshire, UK and a new US facility in Plymouth Meeting near Philadelphia, PA.In April 2012, PsiOxus announced that it would expand into new facilities at the Milton Park in Oxfordshire, UK. The expansion would include a bespoke laboratory for the research and development of novel viral therapeutics; later that month, the facility was opened.By Decem